SynthesisBMC anesthesiology2026
Benefits of nitric oxide administration during cardiopulmonary bypass on postoperative outcomes in adult patients: a meta-analysis and systematic review.
Synthesis in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundNitric oxide (NO) is reported to play several protective roles in the inflammatory response and ischemia/reperfusion injury. This study evaluated the effect of nitric oxide (NO) on postoperative outcomes in adults undergoing cardiac surgery with cardiopulmonary bypass (CPB).
methodsWe systematically searched PubMed, Web of Science, and EMBASE (inception–April 2025) for relevant RCTs. Two reviewers independently screened studies, extracted data, and assessed risk of bias (Cochrane RoB 1) and evidence certainty (GRADE). Meta-analysis was performed using random-effects models.
resultsEight RCTs involving 774 patients were finally included. The use of NO did not reduce the postoperative mortality (RR 0.71, 95% CI 0.36 to 1.42), the duration of postoperative ventilation (MD -0.23 h, 95% CI -1.18 to 0.71), the length of stay in hospital (MD -0.07 days, 95% CI -0.55 to 0.42) or in intensive care unit (MD -4.17 h, 95% CI -8.74 to 0.4). This study demonstrated that NO administration significantly reduced serum levels of creatine kinase-MB at both 24 h (MD -19.36 ng/ml, 95% CI -28.72 to -10.00) and 48 h (MD -17.47 ng/ml, 95% CI -19.53 to -15.41) postoperatively, though it did not affect troponin levels. Concurrently, NO was associated with a significantly lower incidence of postoperative acute kidney injury (RR 0.78, 95% CI 0.64 to 0.93), but not with a reduced need for renal replacement therapy (RR 0.88, 95% CI 0.45 to 1.72).
conclusionsThis meta-analysis of RCTs did not demonstrate a clear benefit of nitric oxide administered via cardiopulmonary bypass on mortality, duration of mechanical ventilation, or length of stay in adult cardiac surgery. Although suggestive renal and cardioprotective signals were observed, these findings are preliminary and require confirmation in larger, methodologically rigorous trials before definitive conclusions can be drawn.
trial registrationINPLASY2022120002.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.